Skip to main content

CellMax Life Receives NT$23M Grant From Taiwan Government for Cancer Early Detection Test

NEW YORK (GenomeWeb) – Liquid biopsy firm CellMax Life said today that it has received an NT$23 million ($760,846) grant from the Taiwan Government Industrial Development Bureau Ministry of Economic Affairs. 

The company plans to use the funding to accelerate its efforts to automate its circulating tumor cell-based technology, and to advance plans for world-wide commercialization of its early cancer detection platform CMxTM.

CellMax Life President and CEO Atul Sharan said in a statement that the grant will allow the company to more rapidly expand the availability of the CMxTM platform and the blood-based screening test the company has developed for colorectal cancer, which it launched in Taiwan last year.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.